Page values for "Naltrexone"

Nav

"Medicines" values

1 row is stored for this page

Field	Field type	Value
generic	`String`	Naltrexone
brand	`String`	ReVia (oral, 50 mg tablets), Depade (oral, generic), Vivitrol (extended-release IM injection 380 mg monthly); Contrave (naltrexone + bupropion ER tablets for weight management)
structure	`File`
classes	List of `String`, delimiter: `,`	[[:Category:Opioid antagonists\|Opioid antagonist (mu and kappa)]] • [[:Category:AUD medicines\|Alcohol use disorder medicine]] • [[:Category:OUD medicines\|Opioid use disorder medicine]]
mechanism	`String`
uses	`String`
starting_dose	`String`
preparations	`String`	Oral tablets 50 mg (ReVia, Depade, generics); Vivitrol extended-release IM suspension 380 mg single-dose vial; Contrave (naltrexone 8 mg + bupropion 90 mg ER tablets); compounded 1, 2, 3, 4.5 mg tablets/capsules for LDN
fda_max	`String`	50 mg/day oral; 380 mg/4 weeks IM (Vivitrol); 32 mg + 360 mg naltrexone/bupropion daily (Contrave maximum after titration)
pill_id	`Text`
routes	List of `String`, delimiter: `,`	Oral • intramuscular (depot)
onset	`String`	Oral peak plasma 1 hour; therapeutic opioid blockade within hours of first dose. IM Vivitrol: peak plasma 2-3 days; therapeutic blockade through the dosing interval.
duration	`String`	Oral mu-blockade clinically meaningful for 24-72 hours; IM Vivitrol blockade through 4 weeks.
halflife	`String`	Naltrexone parent ~4 hours (oral); 6-beta-naltrexol (active metabolite) ~13 hours. Vivitrol depot terminal half-life 5-10 days with sustained release from microspheres maintaining blockade for the 4-week dosing interval.'"`UNIQ--ref-0000004F-QINU`"'
bioavailability	`String`	~5-40% (oral, highly variable due to extensive first-pass metabolism; mean ~5-10% for parent naltrexone with the majority of pharmacologic effect coming from 6-beta-naltrexol). IM Vivitrol bypasses first-pass entirely.'"`UNIQ--ref-00000050-QINU`"'
pregnancy	`String`
legal	`String`